Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Cheng, Ann Lii"" wg kryterium: Autor


Tytuł:
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
Autorzy:
Thompson, Alexander
Danta, Mark
Poursoltan, Pirooz
Kiberu, Andrew
Chittajallu, Renuka
Sood, Siddarth
Stauber, Rudolf
Pinter, Matthias
Peck-Radosavljevic, Markus
Decaestecker, Jochen
Cuyle, Pieter-Jan
Verset, Gontran
Van Vlierberghe, Hans
De Azevedo, Sergio
Andrade, Livia
Cunha Júnior, Ademar
Faria, Luiza
Yen, Cheng Tzu
Colli, Leandro
Asselah, Jamil
Kavan, Petr
Marquez, Vladimir
Brahmania, Mayur
Li, Qiang
Xing, Baocai
Guo, Yabing
Chen, Zhendong
Zhao, Haitao
Peng, Tao
Wang, Liming
Wang, Lu
Liu, Hongming
Wu, Feixiang
Qin, Lunxiu
Zheng, Qichang
Ying, Jieer
Li, Haitao
Wen, Tianfu
Qin, Shukui
Wen, Xiaoyu
Liu, Yunpeng
Chen, Minshan
Wang, Boqing
Bai, Yuxian
He, Yifu
Zhao, Hong
Zhou, Dong
Dai, Chaoliu
Teng, Gaojun
Cui, Shuzhong
Gao, Yi
Zhang, Xizhi
Lu, Zheng
Yin, Tao
Ding, Youming
Jia, Weidong
Xia, Yongxiang
Sun, Beicheng
Xia, Qiang
Yuan, Yufeng
Sun, Huichuan
Shi, Xuetao
Guzmán, Adrián
Corrales, Luis
Kral, Zdenek
Priester, Peter
Kubala, Eugen
Blanc, Jean Frederic
Bourliere, Marc
Peron, Jean Marie
Borg, Christophe
Bronowicki, Jean-Pierre
Ganne, Nathalie
Decaens, Thomas
Uguen, Thomas
Heurgue, Alexandra
Trojan, Joerg
Gonzalez-Carmona, Maria Angeles
Roderburg, Christoph
Ettrich, Thomas
Schotten, Clemens
Kandulski, Arne
Yau, Thomas
Chan, Lam
Scartozzi, Mario
Masi, Gianluca
Fanello, Silvia
Battezzati, Pier Maria
Leonardi, Francesco
Ghidini, Michele
Numata, Kazushi
Morimoto, Manabu
Hidaka, Hisashi
Tsuchiya, Kaoru
Yamashita, Tatsuya
Kato, Naoya
Kudo, Masatoshi
Hagihara, Atsushi
Koga, Hironori
Arakawa, Tomohiro
Nakamura, Ikuo
Kawamura, Yusuke
Kawaoka, Tomokazu
Shimada, Mitsuo
Hasegawa, Kiyoshi
Marusawa, Hiroyuki
Nakamura, Shinchiro
Hiraoka, Atsushi
Hayashi, Hiromitsu
Takeda, Shin
Lee, Han Chu
Paik, Seung Woon
Kim, Do Young
Lee, Jung Il
Jeong, Sook-Hyang
Kim, Won
Tak, Won Young
Heo, Jeong
Kim, Hyeyeong
Chon, Hong Jae
Cheong, Jaeyoun
Yoon, Seung Kew
Yoon, Jung-Hwan
Villalobos, Ricardo
Martinez Rodriguez, Jorge Luis
Oyervides Juarez, Victor
Hernández, Carlos Alberto
Klumpen, Heinz-Josef
de Vos-Geelen, Judith
Gane, Edward
Montenegro, Paola
Torres Mattos, Cesar
Janczewska, Ewa
Kawecki, Maciej
Nowakowska-Zajdel, Ewa
Fedenko, Alexander
Granov, Dmitrii
Alyasova, Anna
Sekacheva, Marina
Ledin, Evgeny
Samol, Jens
Toh, Han Chong
Calvo Campos, Mariona
Gomez Martin, Carlos
Lopez Lopez, Carlos
Muñoz Martin, Andres Jesus
Calleja Panero, Jose Luis
Montero Alvarez, Jose Luis
Reig Monzón, Maria
Delgado Mingorance, Ignacio
Minguez Rosique, Beatriz
Cheng, Ann Lii
Huang, Yi-Hsiang
Lin, Shi-Ming
Huang, Jee-Fu
Yu, Ming-Lung
Su, Wei-Wen
Korphaisarn, Krittiya
Maneenil, Kunlatida
Samdaengpan, Chayanee
Tharavichitkul, Ekkapong
Ozguroglu, Mustafa
Kose, Fatih
Harputluoglu, Hakan
Buchschacher, Gary
Thuluvath, Paul
Xiong, Henry
Patel, Mital
Gold, Philip
Li, Daneng
Brooks, Gabriel
Masood, Ashiq
Patel, Reema
George, Ben
Salgia, Reena
Manji, Gulam
Crow, Mary
Kaseb, Ahmed
Dugan, Matthew
Kadakia, Kunal
Kardosh, Adel
Gibbs, John
Shah, Ashesh
Burris III, Howard
Hsiehchen, David
Cheng, Ann-Lii
Pokaż więcej
Źródło:
In The Lancet 18-24 November 2023 402(10415):1835-1847
Czasopismo naukowe
Tytuł:
Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer
Autorzy:
Chen, Tom Wei-WuAff1, Aff2, Aff3
Hsiao, Wen
Dai, Ming-Shen
Lin, Ching-HungAff1, Aff3
Chang, Dwan-YingAff1, Aff3
Chen, I-ChunAff1, Aff2, Aff3
Wang, Ming-Yang
Chang, Shu-Han
Huang, Shu-Min
Cheng, Ann-LiiAff1, Aff3
Wu, Ko-Wen
Tan, Kien ThiamAff4, IDs10549023069673_cor12
Lu, Yen-ShenAff1, Aff3, IDs10549023069673_cor13
Pokaż więcej
Źródło:
Breast Cancer Research and Treatment. 201(3):377-385
Czasopismo naukowe
Tytuł:
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
Autorzy:
Strasser, Simone
Thompson, Alexander
Roohullah, Aflah
Sievert, William
Andelkovic, Vladimir
Knox, Jennifer
Davies, Janine
Asselah, Jamil
Brahmania, Mayur
Majeed, Habeeb
Villanueva, Luis
Yanez Weber, Patricio
Garrido, Marcelo
Pizarro, Gonzalo Ignacio
Yanez, Nicolas
Xu, Ruocai
Ou, Shuangyan
Ren, Zhenggang
Pan, Hongming
Meng, Zhiqiang
Gu, Kangsheng
Chen, Xi
Zhang, Tao
Hao, Chunyi
Cao, Peiguo
Guo, Yabing
Qin, Shukui
Xiao, Juxiang
Fang, Weijia
Wang, Xin
Bai, Yuxian
Chen, Xiaoming
Yan, Dong
Zhao, Hong
Ying, Jieer
Bonilla, Carlos
Urrego, Olga
Zambrano, Angela
Lema, Mauricio
Restrepo Gutierrez, Juan Carlos
Cardona, Andres
Franco Millan, Sandra
Oscar, Madiedo
Ramos, Victor
Merle, Philippe
LeSourd, Samuel
Edeline, Julien
Bronowicki, Jean-Pierre
Bourliere, Marc
Cattan, Stephane
Bouattour, Mohamed
Mineur, Laurent
Regnault, Helene
Dauvois, Barbara
Schulze, Kornelius
Folprecht, Gunnar
Geier, Andreas
Waidmann, Oliver
Finkelmeier, Fabian
Venerito, Marino
Berres, Marie-Luise
Berg, Thomas
Lange, Christian
Schmidt, Hartmut
Waldschmidt, Dirk T
Bitzer, Michael
McDermott, Ray
Duffy, Austin
Masi, Gianluca
Zagonel, Vittorina
Tonini, Giuseppe
Piscaglia, Fabio
Gori, Stefania
Rizzo, Mimma
Biscaldi, Elisa
Foltran, Luisa
Cabibbo, Giuseppe
Ikeda, Masafumi
Kudo, Masatoshi
Aikata, Hiroshi
Numata, Kazushi
Marusawa, Hiroyuki
Kato, Naoya
Kurosaki, Masayuki
Morimoto, Manabu
Yamashita, Tatsuya
Koga, Hironori
Masaki, Tsutomu
Tateishi, Ryosuke
Inaba, Yoshitaka
Arakawa, Tomohiro
Suzuki, Yoshiyuki
Akua, Norio
Kobayashi, Masahiro
Hosaka, Tetsuya
Nakamuta, Makoto
Oza, Noriko
Kondo, Shunsuke
Furuse, Junji
Nagashima, Fumio
Kitano, Masayuki
Takaguchi, Koichi
Ryoo, Baek-Yeol
Lim, Ho Yeong
Kim, Jee Hyun
Kim, Tae-You
Kim, Han Sang
Hernandez Hernandez, Carlos
Motola Kuba, Daniel
Segura Gonzalez, Manuel
Cabrera Luviano, Jesus
Huitzil Melendez, Fidel
Ramirez Godinez, Francisco
Silva-Bravo, Fernando
Gane, Edward
Stedman, Catherine
Kwiatkowski, Mariusz
Wyrwicz, Lucjan
Nowakowska-Zajdel, Ewa
Kraj, Leszek
Janczewska, Ewa
Surma-Wlodarczyk, Renata
Breder, Valeriy
Sekacheva, Marina
Orlova, Rashida
Vasilyev, Alexander
Zukov, Ruslan
Vladimirov, Vladimir
Minguez, Beatriz
Matilla Pena, Ana
Fernandez Castroagudin, Javier
Romero Gomez, Manuel
Luis Lledo, Jose
Rubin, Angel
Garcia Sanchez, Araceli
Calleja Panero, Jose
Yu, Ming-Chin
Shen, Ying-Chun
Huang, Yi-Hsiang
Jeng, Long-Bin
Chang, Ting-Tsung
Yang, Sheng-Shun
Chen, Shinn-Cherng
Dechaphunkul, Arunee
Tanwandee, Tawesak
Leerapun, Apinya
Seker, Mesut
Harputluoglu, Hakan
Cicin, Irfan
Oksuzoglu, Berna
Bilici, Mehmet
Sezgin Goksu, Sema
Artac, Mehmet
Cil, Timucin
Yalcin, Suayib
Meyer, Tim
Sarker, Debashis
Rao, Ankit
Palmer, Daniel
Evans, Jeff
Hubner, Richard
Finn, Richard
Ulahannan, Susanna
Zakari, Ahmed
Feun, Lynn
Al-Rajabi, Raed
Sung, Max
He, Aiwu
Kardosh, Adel
Goyal, Lipika
Li, Daneng
Choi, Minsig
Posada, Juan
Dodlapati, Jyothi
Shroff, Rachna
Agrawal, Saurabh
Gopaluni, Srivalli
Akce, Mehmet
Alese, Olatunji
Baron, Ari
Dunne, Richard
Loaiza-Bonilla, Arturo
Frenette, Catherine
Llovet, Josep M
Kumada, Hiromitsu
Cheng, Ann-Lii
Galle, Peter R
Kaneko, Shuichi
Wang, Anran
Mody, Kalgi
Dutcus, Corina
Dubrovsky, Leonid
Siegel, Abby B
Finn, Richard S
Pokaż więcej
Źródło:
In The Lancet Oncology December 2023 24(12):1399-1410
Czasopismo naukowe
Tytuł:
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Autorzy:
Qin, Shukui
Chan, Stephen L
Cheng, Ann-Lii
Kaseb, Ahmed
Vogel, Arndt
Gu, Shanzhi
Bai, Yuxian
Ren, Zhenggang
Lin, Xiaoyan
Chen, Zhendong
Jia, Weidong
Jin, Yongdong
Guo, Yabing
Hu, Xiaohua
Meng, Zhiqiang
Liang, Jun
Cheng, Ying
Xiong, Jianping
Ren, Hong
Yang, Fang
Li, Wei
Chen, Yajin
Zeng, Yong
Sultanbaev, Alexander
Pazgan-Simon, Monika
Pisetska, Margaryta
Melisi, Davide
Ponomarenko, Dmitriy
Osypchuk, Yurii
Sinielnikov, Ivan
Yang, Tsai-Sheng
Liang, Xiao
Chen, Chunxia
Wang, Linna
Zhang, Mingxiang
Xu, Li
Yuan, Xianglin
Li, Da
Ying, Jierer
Zhang, Jingdong
Zhang, Tao
Gu, Kangsheng
He, Yifu
Hao, Ping
Jiang, Da
Zhang, Shu
Xing, Baocai
Zhang, Baihong
Wang, Dong
Zhai, Xiaofeng
Liang, Houjie
Cybulska-Stopa, Bozena
Dvorkin, Mikhail
Stroyakovskiy, Daniil
Nechaeva, Marina
Yen, Chia-Jui
Su, Wei-Wen
Chen, Yen-Hao
Bondarenko, Igor
Yang, Lin
Fang, Weijia
Gomez-Martin, Carlos
Ryu, Min-Hee
Kim, Han-Sang
Kim, Jee-Hyun
Zarubenkov, Oleg
Orlova, Rashida
Poddubskaya, Elena
Fadeeva, Natalia
Makarova, Yulia
Chao, Yee
Hung, Chao-Hung
Neffa, Maryna
Vynnychenko, Oleksandr
Burgoyne, Adam
Hao, Chunyi
Mohr, Raphael U
Diaz-Beveridge, Roberto
Feliu-Batlle, Jaime
Cubillo-Gracian, Antonio
Lee, Ann-Shing
Daniele, Bruno
Antonuzzo, Lorenzo
Sangiovanni, Angelo
Gasbarrini, Antonio
Scartozzi, Mario
Ahn, Mi Sun
Oh, Sung-Yong
Orlov, Sergey
Harputluoglu, Hakan
Oksuzoglu, Berna
Hsu, Chiun
Rau, Kun-Ming
Krechkovskyi, Oleksandr
Yareshko, Vladimir
Xiong, Henry
Lee, Fa-Chyi
Jiang, Yixing
Gabayan, Afshin
Crow, Mary
Van Steenkiste, Christophe
Verset, Gontran
Pokaż więcej
Źródło:
In The Lancet 30 September-6 October 2023 402(10408):1133-1146
Czasopismo naukowe
Czasopismo naukowe
Tytuł:
Primary effusion anaplastic large cell lymphoma with indolent clinical course and IRF4/DUSP22 rearrangement: a case report expanding the spectrum of effusion-based lymphoma
Autorzy:
Yuan, Chang-TsuAff1, Aff2, Aff3
Cheng, Ann-Lii
Hou, Hsin-AnAff5, IDs00428022033856_cor3
Pokaż więcej
Źródło:
Virchows Archiv: European Journal of Pathology. 482(3):641-645
Czasopismo naukowe
Tytuł:
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial
Autorzy:
Kelley, Robin Kate
Cheng, Ann-Lii
Kaseb, Ahmed
Qin, Shukui
Zhu, Andrew X
Chan, Stephen L
Melkadze, Tamar
Sukeepaisarnjaroen, Wattana
Breder, Valery
Verset, Gontran
Gane, Edward
Borbath, Ivan
Rangel, Jose David Gomez
Ryoo, Baek-Yeol
Makharadze, Tamta
Merle, Philippe
Benzaghou, Fawzi
Banerjee, Kamalika
Hazra, Saswati
Fawcett, Jonathan
Yau, Thomas
Pokaż więcej
Źródło:
In The Lancet Oncology August 2022 23(8):995-1008
Czasopismo naukowe
Tytuł:
Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma
Autorzy:
Chen, Bang-BinAff1, Aff2
Liang, Po-ChinAff1, Aff2, Aff3
Shih, Tiffany Ting-FangAff1, Aff2
Liu, Tsung-HaoAff4, Aff5, Aff6
Shen, Ying-ChunAff4, Aff5, Aff6
Lu, Li-ChunAff4, Aff5, Aff6
Lin, Zhong-ZheAff4, Aff6
Hsu, ChiunAff4, Aff5, Aff6
Hsu, Chih-HungAff4, Aff5, Aff6
Cheng, Ann-LiiAff4, Aff5, Aff6, Aff7
Shao, Yu-YunAff4, Aff5, Aff6, IDs00330022089804_cor11
Pokaż więcej
Źródło:
European Radiology. 33(1):512-522
Czasopismo naukowe
Tytuł:
Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment
Autorzy:
Chen, Ching-TsoAff1, Aff2
Feng, Yin-Hsun
Yen, Chia-Jui
Chen, San-Chi
Lin, Yun-Tzu
Lu, Li-ChunAff2, Aff6, Aff8
Hsu, Chih-HungAff2, Aff6, Aff8
Cheng, Ann-LiiAff2, Aff6, Aff7, Aff8
Shao, Yu-YunAff2, Aff6, Aff8, IDs1207202210392x_cor9
Pokaż więcej
Źródło:
Hepatology International. 16(5):1199-1207
Czasopismo naukowe
Tytuł:
Deleterious alterations of DNA damage response and repair genes and clinical benefit to anti-PD-1 therapy in esophageal squamous cell carcinoma
Autorzy:
Guo, Jhe-CyuanAff1, Aff2, Aff4
Lin, Chia-ChiAff1, Aff2, Aff4
Hsu, Chia-Lang
Huang, Ta-ChenAff2, Aff5
Kuo, Hung-YangAff2, Aff5
Lin, Chen-Yuan
Lien, Ming-Yu
Cheng, Ann-LiiAff1, Aff2, Aff5
Hsu, Chih-HungAff1, Aff2, Aff5, IDs10388022009407_cor9
Pokaż więcej
Źródło:
Esophagus. 19(4):693-701
Czasopismo naukowe
Tytuł:
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
Autorzy:
Galle, Peter R
Finn, Richard S
Qin, Shukui
Ikeda, Masafumi
Zhu, Andrew X
Kim, Tae-You
Kudo, Masatoshi
Breder, Valeriy
Merle, Philippe
Kaseb, Ahmed
Li, Daneng
Mulla, Sohail
Verret, Wendy
Xu, Derek-Zhen
Hernandez, Sairy
Ding, Beiying
Liu, Juan
Huang, Chen
Lim, Ho Yeong
Cheng, Ann-Lii
Ducreux, Michel
Pokaż więcej
Źródło:
In The Lancet Oncology July 2021 22(7):991-1001
Czasopismo naukowe
Tytuł:
Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy
Autorzy:
Huang, Ta-ChenAff1, Aff2
Liang, Cher-Wei
Li, Yu-I
Guo, Jhe-CyuanAff2, Aff5
Lin, Chia-Chi
Chen, Ya-Jhen
Cheng, Ann-LiiAff1, Aff2, Aff3, Aff5, IDs00432021037727_cor7
Hsu, Chih-HungAff1, Aff2, Aff5, IDs00432021037727_cor8
Pokaż więcej
Źródło:
Journal of Cancer Research and Clinical Oncology. 148(7):1803-1811
Czasopismo naukowe
Tytuł:
Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial
Autorzy:
El-Khoueiry, Anthony B.Aff1, IDs1288502209453z_cor1
Meyer, Tim
Cheng, Ann-Lii
Rimassa, LorenzaAff4, Aff5
Sen, Suvajit
Milwee, Steven
Kelley, Robin Kate
Abou-Alfa, Ghassan K.Aff8, Aff9
Pokaż więcej
Źródło:
BMC Cancer. 22(1)
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies